摘要
目的 分析亚胺培南西司他丁联合利奈唑胺治疗老年重症肺炎的疗效及对细胞免疫功能和预后的影响。方法 选取确诊的96例老年重症肺炎患者,采用简单随机分组法将患者分为观察组和对照组,各48例。对照组采用亚胺培南西司他丁治疗,观察组采用亚胺培南西司他丁联合利奈唑胺治疗。比较2组患者治疗前后的临床疗效、免疫功能和炎症指标,观察不良反应发生情况;记录患者治疗后28 d的病死率。结果 治疗后,观察组治疗总有效率(91.67%)明显高于对照组(72.91%),P<0.05;观察组表面抗原分化簇3受体(differentiation cluster 3 receptor,CD3+)、表面抗原分化簇4受体(differentiation cluster 4 receptor,CD4+)和CD4+/表面抗原分化簇8受体(differentiation cluster 8 receptor,CD8+)(CD4+/CD8+)细胞所占比例均高于对照组(P<0.05);2组病人的血清炎性因子水平均降低,观察组血清白细胞介素-6(interleukin-6,IL-6)、降钙素原(pro calcitonin,PCT)、超敏C反应蛋白(high sensitivity C-reactive protein,CRP)和白细胞(white blood cell,WBC)水平均明显低于对照组(P<0.05);观察组不良反应发生率(8.33%)与对照组(12.50%)比较差异无统计学意义(P>0.05);观察组临床肺部感染评分(clinical pulmonary infection score,CPIS)和重症监护室(intensive care unit,ICU)入住时间明显低(短)于对照组(P<0.05);治疗后28 d 2组病死率比较差异无统计学意义(P>0.05)。结论 亚胺培南西司他丁联合利奈唑胺治疗老年重症肺炎疗效显著,能增强老年重症肺炎患者的免疫防御能力,改善预后。
Objective To analyze the effects of imipenem-cilastatin combined with linezolid on cellular immune function and prognosis in elderly patients with severe pneumonia.Methods A total of 96 elderly patients with severe pneumonia confirmed in the hospital were enrolled.They were divided into observation group and control group by simple random grouping method,48 cases in each group.The control group were treated with imipenem-cilastatin,while the observation group were additionally treated with linezolid.The clinical curative effect,immune function and inflammatory indexes between the 2 groups were compared before and after treatment.The occurrence of adverse reactions was observed,and the mortality rate at the 28th days after treatment was recorded.Results After treatment,the total response rate of treatment in observation group was significantly higher than that in control group(91.67%vs.72.91%)(P<0.05).After treatment,the levels of differentiation cluster 3 receptor(CD3+),differentiation cluster 4 receptor(CD4+)and CD4+/differentiation cluster 8 receptor(CD8+)(CD4+/CD8+)in observation group were higher than those in control group(P<0.05).After treatment,the levels of serum inflammatory factors in both groups were decreased.The levels of serum interleukin-6(IL-6),procalcitonin(PCT),high sensitivity C-reactive protein(CRP)and white blood cells(WBC)in observation group were significantly lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(8.33%vs.12.50%)(P>0.05).After treatment,the clinical pulmonary infection score(CPIS)score and stay time in intensive care unit(ICU)in observation group were significantly lower than those in control group(P<0.05).There was no significant difference in 28 days mortality rate between the 2 groups(P>0.05).Conclusion The curative effect of imipenem-cilastatin combined with linezolid is significant in elderly patients with severe pneumonia,which can enhance the immune defense ability and improve the progn
作者
宋林燕
杨晓帆
黄正米
程辉
SONG Linyan;YANG Xiaofan;HUANG Zhengmi;CHENG Hui(Department of Critical Care Medicine,Anqing First People's Hospital of Anhui Medical University,Anqing 246000,China;Department of Cardiovascular Medicine,Anqing First People's Hospital of Anhui Medical University,Anqing 246000,China)
出处
《西北药学杂志》
CAS
2023年第3期172-175,共4页
Northwest Pharmaceutical Journal
基金
2020年度皖南医学院教学医院科研专项项目(编号:JXYY202028)。
